Vapitadine

Vapitadine

SCHEMBL3463472

Cl.Cl.NC(=O)c1cnc2n1CCc1ccccc1C21CCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of Vapitadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 2/20 1.00
HTR2A P28223 4/20 0.41
HTR2C P28335 3/20 0.36
DRD2 P14416 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
CCNC P24863 1/20 0.32
CDK8 P49336 1/20 0.32
HASPIN Q8TF76 1/20 0.32
HTR2B P41595 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
BACE1 P56817 1/20 0.30
BTK Q06187 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vapitadine SCHEMBL29379463 0.99 HRH1 (1.00) HRH1HTR2AHTR2CDRD2SLC6A2
Vapitadine SCHEMBL6440903 0.99 HRH1 (1.00) HRH1HTR2AHTR2CDRD2SLC6A2
SCHEMBL6440008 0.88 HRH1 (0.80) HRH1HTR2AHTR2CHTR2BSIGMAR1
Water SCHEMBL6031226 0.87 HRH1 (0.78) HRH1HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL6029703 0.86 HRH1 (0.77) HRH1HTR2AHTR2CSLC6A2HTR2B
Hydrochloric Acid SCHEMBL6440622 0.84 HRH1 (0.73) HRH1HTR2AHTR2CDRD2SLC6A2
SCHEMBL6030546 0.83 HRH1 (0.72) HRH1HTR2AHTR2CHTR2BSIGMAR1
SCHEMBL6031708 0.82 HRH1 (0.71) HRH1HTR2AHTR2CDRD2HTR2B
SCHEMBL6031453 0.80 HRH1 (0.67) HRH1
Hydrochloric Acid SCHEMBL6030979 0.79 HRH1 (0.65) HRH1HTR2AHTR2CDRD2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148214-B1 Antihistaminic spiro compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-12 US claimed
US-7087595-B2 Antihistaminic spiro compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-08 US claimed
EP-1144411-B1 ANTIHISTAMINIC SPIRO COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2005-04-27 EP claimed
US-20050026901-A1 Antiallergens; vision disorders JANSSENS FRANS EDUARD (BE) 2005-02-03 US claimed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
EP-1922313-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-05-21 EP disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed
US-7148214-B1 Antihistaminic spiro compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-12 US disclosed
US-7087595-B2 Antihistaminic spiro compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-08 US disclosed
EP-1144411-B1 ANTIHISTAMINIC SPIRO COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2005-04-27 EP disclosed
US-20050026901-A1 Antiallergens; vision disorders JANSSENS FRANS EDUARD (BE) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026901-A1 Antiallergens; vision disorders UACA, LTB4R, HLA-B HRH1 35/4885HTR2A 3106/4885HTR2C 4010/4885
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 HRH1 237/4885HTR2A 23/4885HTR2C 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.